Crohn's Disease (cont.)
In this Article
- Crohn's disease facts
- What is Crohn's disease?
- What causes Crohn's disease?
- How does Crohn's disease affect the intestines?
- How is Crohn's disease different from ulcerative colitis?
- What are the symptoms of Crohn's disease?
- What are the complications of Crohn's disease?
- How is Crohn's disease diagnosed?
- How is Crohn's disease treated?
- Crohn's Disease Medications
- Anti-inflammatory medications
- 5-ASA (mesalamine) oral medications
- 5-ASA rectal medications (Rowasa, Canasa)
- Budesonide (Entocort EC)
- Antibiotics for Crohn's disease
- Immuno-modulator medications
- Azathioprine (Imuran) and 6-mercaptopurine (6-MP, Purinethol)
- Infliximab (Remicade)
- Adalimumab (Humira)
- Certolizumab pegol (Cimzia)
- Natalizumab (Tysabri)
- Methotrexate (Rheumatrex, Trexall)
- Surgery in Crohn's disease
- Are there any recommendations for diet, supplementation, or vaccinations for Crohn's disease?
- View the Crohn's Disease Slideshow
- Crohn's Disease Quiz
- Inflammatory Bowel Disease (IBD) Slideshow
- Crohn's Disease FAQs
- Find a local Gastroenterologist in your town
Natalizumab (Tysabri) is a humanized monoclonal antibody to alpha-4 integrin and is effective in treatment of patients with moderate to severe CD and evidence of inflammation who have not responded to aminosalicylates, antibiotics, corticosteroids, immunomodulators, or TNF inhibitors. This medication targets the cellular adhesion molecule alpha-4 integrin, which is expressed on leukocytes or white blood cells which are known to play a role in the pathogenesis of Crohn's disease7. Patient's who are registered through the CD TOUCH prescribing program may prescribe this medication to patients. Natalizumab was approved by the Food and Drug Administration in 2008 for this use, but has been used prior to this time for some forms of multiple sclerosis.
The recommended dose of Tysabri is 300mg IV infusion over 1 hour every four weeks. It should not be used with concomitant immunosuppressants or TNF-alpha inhibitors.
Side Effects of natalizumab (Tysabri)
The most common adverse effects reported have been headache, fatigue, upper respiratory infections, and nausea. The most serious adverse events reported have been hypersensitivity, immunosuppression/infections and progressive multifocal leukoencephalopathy.7
Progressive multifocal leukoencephalopathy (PML) has developed in patients treated with natalizumab. PML is caused by reactivation of a latent virus, the human JV polyoma virus, which can lead to infection of the CNS that is typically fatal. Infectious complications with other organisms may also be increased. This medication usually is well tolerated, but has been associated with acute hypersensitivity infusion reactions. Patients might also develop anti-natalizumab antibodies and liver toxicity.
All patients started on this drug must be monitored through the TOUCH program whose purpose is to monitor patients for signs and symptoms of PML and to assess the incidence of opportunistic infections.
Find out what women really need.